Table 2 Association between E2F2 expression and clinicopathologic characteristics (logistic regression)

Age (>40 vs. ≤40)

370

1.48 (0.73–3.09)

0.28

Gender (male vs. female)

371

0.72 (0.46–1.11)

0.14

BMI(≥25 vs.<25)

335

0.96 (0.63–1.48)

0.87

Family history of cancer (yes vs. no)

320

0.85 (0.53–1.34)

0.48

Histologic grade (G3–4 vs. G1–2)

366

2.62 (1.69–4.10)

1.80E-05

Clinical stage (III-IV vs. I-II)

347

1.74 (1.07–2.85)

0.03

T (T3–4 vs. T1–2)

368

1.64 (1.02–2.65)

0.04

N (N1 vs. N0)

256

1.00 (0.12–8.44)

1.00

M (M1 vs. M0)

270

0.33 (0.02–2.60)

0.34

Residual tumor (R1–2 vs. R0)

342

2.08 (0.79–6.08)

0.15

Tumor status (with tumor vs. tumor free)

352

1.88 (1.20–2.89)

3.79E-03

Vascular invasion (yes vs. no)

315

1.23 (0.77–1.96)

0.38

Child-Pugh (B-C vs. A)

239

1.01 (0.42–2.45)

0.98

 AFP ≥ 400 vs. AFP<20

217

3.18 (1.74–5.94)

2.16E-04

 20 ≤ AFP < 400 vs. AFP<20

219

2.50 (1.39–4.58)

2.56E-03

 AFP ≥ 400 vs. 20 ≤ AFP < 400

132

1.27 (0.62–2.61)

0.51

New tumor event (yes vs. no)

269

1.48 (0.97–2.26)

0.07

 W > 1000 vs. W ≤ 500

268

1.26 (0.51–3.23)

0.62

 1000 ≥ W > 500 vs. W ≤ 500

278

1.18 (0.55–2.55)

0.67

 W > 1000 vs.1000 ≥ W > 500

50

1.07 (0.34–3.38)

0.91

 HBV&HCV vs. HBV

141

1.13 (0.58–2.21)

0.72

 HCV vs. HBV

79

0.62 (0.21–1.68)

0.35

 HBV&HCV vs. HCV

104

1.83 (0.70–5.07)

0.23

History of alcohol consumption (yes vs. no)

358

1.08 (0.69–1.68)

0.73

Postoperative ablation embolization (yes vs. no)

353

1.59 (0.73–3.61)

0.25

Radiation therapy (yes vs. no)

352

1.69 (0.41–8.33)

0.48